← Leaderboards
Pravin Tp Kaumaya
Ohio State University
$3,865,410
Attributed
$6,222,155
Total exposure
7
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $752.7K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$6,222,155 · 7
By mechanism
R01$4,222,421 · 3
R21$1,979,501 · 3
M01$20,233 · 1
Top collaborators
- Pedro Cabrales4 shared
- Andre Francis Palmer4 shared
- Tanios Bekaii-Saab2 shared
- William E. Carson2 shared
Most similar at Ohio State University
Same institution · by research overlap
- Michael D Lairmore$5,085,750
- Jeffrey John Chalmers$7,748,895
- David W Wood$1,754,888
- Ming-Daw Tsai$6,744,909
- Jay Louis Zweier$32,737,666
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseVaccine DevelopmentSynthetic VaccinesNonhuman Therapy EvaluationOncoproteinsClinical TrialsGenetically Modified AnimalsNeoplasm /Cancer VaccineImmune ResponseNeoplasm /Cancer ImmunologyAntitumor AntibodyPreventSynthetic PeptideIn VivoAntibodiesBaseDrug Screening /EvaluationCostGenerationsClinical ResearchImmune SystemImmunogenicityToxic EffectBiotechnology
Grant awards (20)
PEGylated megahemoglobin for use as a red blood cell substitute$695,646
R01 · FY2020 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$708,669
R01 · FY2019 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$718,085
R01 · FY2018 · HL
PEGylated megahemoglobin for use as a red blood cell substitute$752,718
R01 · FY2017 · HL
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2010 · CA · contact PI
Phase I Trial with Two HER-2 B Cell Epitope Vaccine in Patients with Solid Tumors$330,000
R21 · FY2009 · CA · contact PI
PHASE I TRIAL WITH CHIMERIC AND MULTI-EPITOPE BASED PEPTIDE VACCINES$8,754
M01 · FY2005 · RR
Phase I Trial--Chimeric Multi-epitope Peptide Vaccines$11,479
M01 · FY2004 · RR
Phase 1b Active Immunotherapy with HER-2 Multi-epitope v$328,188
R21 · FY2003 · CA
CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIES$229,950
R01 · FY2003 · CA
Peptide Therapeutic Approaches for Immune Tolerance$221,250
R21 · FY2003 · AI
Phase 1b Active Immunotherapy with HER-2 Multi-epitope v$328,188
R21 · FY2002 · CA
CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIES$229,950
R01 · FY2002 · CA
Peptide Therapeutic Approaches for Immune Tolerance$221,250
R21 · FY2002 · AI
CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIES$229,950
R01 · FY2001 · CA
Peptide Therapeutic Approaches for Immune Tolerance$220,625
R21 · FY2001 · AI
STRUCTURE/CONFORMATION ASPECTS IN PEPTIDE VACCINES$216,860
R01 · FY2001 · AI
CHIMERIC AND MULTIVALENT HER 2 CANCER VACCINE STRATEGIES$229,950
R01 · FY2000 · CA
STRUCTURE/CONFORMATION ASPECTS IN PEPTIDE VACCINES$206,263
R01 · FY2000 · AI
STRUCTURE/CONFORMATION ASPECTS IN PEPTIDE VACCINES$4,380
R01 · FY2000 · AI